Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (1061-1070 of 1,095) with videos related to

Pageof 110
Sort By:
European Urology Oncology|July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Minerva Urology and Nephrology|August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinationsCamillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Eclinicalmedicine|July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational studyMelissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
The Oncologist|May 20, 2026
Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy CombinationsSara Elena Rebuzzi, Aruni Ghose, Sarah Rudman, et al.
Journal of Hepatology|June 21, 2024
Sex and ethnic disparities in hepatitis B evaluation and treatment across the worldSahith Kudaravalli, Daniel Q Huang, Ming-Lun Yeh, et al.
Journal of Personalized Medicine|May 28, 2022
Validation of a Novel Three-Dimensional (<i>3D Fusion</i>) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 StudyMatteo Brunelli, Guido Martignoni, Giorgio Malpeli, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2010
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, et al.
Therapeutic Advances in Medical Oncology|November 23, 2020
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOGMelissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
Pageof 110

Showing results (1061-1070 of 1,095) with videos related to

Sort By:
Pageof 110
European Urology Oncology|July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Minerva Urology and Nephrology|August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinationsCamillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Eclinicalmedicine|July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational studyMelissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
The Oncologist|May 20, 2026
Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy CombinationsSara Elena Rebuzzi, Aruni Ghose, Sarah Rudman, et al.
Journal of Hepatology|June 21, 2024
Sex and ethnic disparities in hepatitis B evaluation and treatment across the worldSahith Kudaravalli, Daniel Q Huang, Ming-Lun Yeh, et al.
Journal of Personalized Medicine|May 28, 2022
Validation of a Novel Three-Dimensional (<i>3D Fusion</i>) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 StudyMatteo Brunelli, Guido Martignoni, Giorgio Malpeli, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2010
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, et al.
Therapeutic Advances in Medical Oncology|November 23, 2020
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOGMelissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
Pageof 110